Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Immunodiagnostics group Oncimmune said it had signed a collaboration agreement with Roche company Genentech.
The companies would work to characterise the autoantibody profiles of patients in clinical trials for rheumatological diseases, including systemic lupus erythematosus.
Oncimmune would use its proprietary NavigAID panel to characterise autoantibody profiles from trial participants.
Genentech would have an option to expand the contract to profile additional samples.
At 9:46am: (LON:ONC) Oncimmune Holdings Plc share price was +4p at 143.5p